Fei Cao
Chief Executive Officer presso HUBEI JUMPCAN PHARMACEUTICAL CO., LTD.
Patrimonio netto: 368 311 $ in data 29/02/2024
Profilo
Fei Cao holds the position of Vice Chairman & General Manager at Hubei Jumpcan Pharmaceutical Co., Ltd.
He is also on the board of Jumpcan Pharmaceutical Co. Ltd.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
13/09/2022 | 1 961 500 ( 0.15% ) | 368 311 $ | 29/02/2024 |
Posizioni attive di Fei Cao
Società | Posizione | Inizio |
---|---|---|
HUBEI JUMPCAN PHARMACEUTICAL CO., LTD. | Chief Executive Officer | 20/12/2019 |
Jumpcan Pharmaceutical Co. Ltd.
Jumpcan Pharmaceutical Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of Hubei Jumpcan Pharmaceutical Co., Ltd., Jumpcan Pharmaceutical Co. Ltd. is a pharmaceutical company based in Taixing, China. The Chinese company offers a range of products including mouthwash, cough medicine, and pain relief ointments. The CEO of the private company is Long Xiang Cao. Jumpcan Pharmaceutical Co. was acquired by Hubei Jumpcan Pharmaceutical Co., Ltd. from Jiangsu Jichuan Holdings Group Co. Ltd. on December 20, 2013 for $911.88 million. | Director/Board Member | - |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
HUBEI JUMPCAN PHARMACEUTICAL CO., LTD. | Health Technology |
Aziende private | 1 |
---|---|
Jumpcan Pharmaceutical Co. Ltd.
Jumpcan Pharmaceutical Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of Hubei Jumpcan Pharmaceutical Co., Ltd., Jumpcan Pharmaceutical Co. Ltd. is a pharmaceutical company based in Taixing, China. The Chinese company offers a range of products including mouthwash, cough medicine, and pain relief ointments. The CEO of the private company is Long Xiang Cao. Jumpcan Pharmaceutical Co. was acquired by Hubei Jumpcan Pharmaceutical Co., Ltd. from Jiangsu Jichuan Holdings Group Co. Ltd. on December 20, 2013 for $911.88 million. | Health Technology |